Developer docs
API playgroundTry for free, no card

Search company profiles

Fund+

Full company profile

uuid0005apz

Namestring
Fund+
Legal namestring
Fundplus
Websiteurl
fundplus.be
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Fund+ is a Belgian venture capital firm established in 2015, headquartered at Groot Begijnhof 60 in Leuven. The firm operates as an open-ended fund providing long-term equity investment in innovative life sciences companies, with a primary focus on Belgium and the broader Benelux region while extending into select European markets including Germany, the Netherlands, and Spain. Fund+ invests across therapeutics, medical devices, and diagnostics, with a stated emphasis on patient-centric approaches addressing unmet medical needs in oncology, CNS disorders, rare diseases, infectious diseases, and regenerative medicine.

The firm manages a portfolio of approximately 16-17 companies spanning modalities such as antibody-drug conjugates (Tubulis, Ona Therapeutics), RNA therapeutics (Cardior), gene therapy (Coave Therapeutics), regenerative tissue products (Novadip Biosciences), vaccines (AstriVax Therapeutics), GPCR-modulating therapies (Confo Therapeutics), and continuous monitoring devices (Indigo Diabetes). Notable portfolio events include Fund+ leading the €42M Series A for ExeVir Bio (co-founded with VIB and UCB in 2020) and the €38M Series B for Indigo Diabetes, as well as participation in Tubulis' €60M Series B (2022), €128M Series B2 (2024), and €308M Series C (2025), the latter being the largest Series C financing for a European biotech.

Fund+'s revenue model combines management fees on assets under management with capital appreciation from equity investments realized through exits. As of 2022 the firm managed over €200M in AUM. Two major exits anchor the track record: Cardior's acquisition by Novo Nordisk in March 2024 for up to €1.025B, and Tubulis' acquisition by Gilead Sciences in April 2026 for $3.15B upfront plus up to $1.85B in milestone payments. The firm is led by founder and chairman Desire Collen and a specialist team combining healthcare industry, corporate finance, and strategy consulting experience, distributing capital via direct equity investments and active engagement with portfolio boards.

Short descriptiontext

Fund+ is a Belgian venture capital firm founded in 2015 that provides long-term equity investment to innovative life sciences companies across therapeutics, medical devices, and diagnostics, primarily in Belgium and the broader Benelux and European markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLeuven, Belgium
HQ citystring
Leuven
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences venture capital, biotech equity investment, therapeutics funding, medical devices investment, diagnostics venture capital
Industry1 code
PRIMARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
NAICS code1 code
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Life Sciences Investment Management
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Capital Appreciation
TypeLicensing Royalties
Description

Fund+ generates returns through capital appreciation from equity investments in portfolio companies. As an open-ended fund for long-term equity investment, returns are realized through exits of portfolio companies via acquisitions or IPOs.

fundplus.be
2Investment Management Fees
TypeSubscription Recurring
Description

Fund+ charges management fees for overseeing the fund and its portfolio companies, supporting companies throughout their growth cycle.

fundplus.be
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Pricing details1 tier
1Long-term equity investment in life sciences companies
ModelOtherBilling cadenceMulti-year contract
Notes

Investment terms based on individual deal negotiations with portfolio companies. Focus on Benelux and European innovative life sciences companies developing drugs, medical devices and diagnostics.

fundplus.be
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Fund+ is an open-ended venture capital fund providing long-term equity investment to innovative European life sciences companies with a focus on Belgium and the Benelux region. The fund invests across stages in therapeutics, medical devices, and diagnostics companies addressing unmet medical needs, supporting them through their growth cycles with capital and strategic guidance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Tubulis acquisition by Gilead for $3.15B upfront + $1.85B milestones
+1 more record
Product overview1 text field

Fund+ is an open-ended venture capital fund for long-term equity investment in innovative European Life Sciences companies. The fund focuses on Belgium and Benelux, investing in therapeutics with a strong patient-centric approach and addresses unmet medical needs. Fund+ creates sustainable shareholder value while reinforcing Belgium's leading position in the Life Sciences sector and generating tangible societal benefits.

Product and service1 record
1Fund+ Life Sciences Investment Fund
CategoryVenture Capital / Private Equity Fund
Description

An open-ended venture capital fund providing long-term equity investment to innovative European Life Sciences companies, with primary focus on Belgium and Benelux. Invests in therapeutics, medical devices, and diagnostics companies addressing unmet medical needs, with a patient-centric approach. Supports portfolio companies throughout their growth cycles from seed to later stages.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Fund+ established ExeVir Bio with VIB and UCB in July 2020 to accelerate COVID-19 treatments. Fund+ led the €42M Series A. ExeVir develops single-domain antibody therapies for infectious diseases with candidates targeting SARS-CoV-2 variants and dengue.

2VIB
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

VIB (Flanders Institute for Biotechnology) is Belgium's leading life sciences research institute. Fund+ co-founded ExeVir Bio with VIB and UCB. VIB provides scientific expertise and research capabilities for portfolio companies.

fundplus.be
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

UCB collaborated with Fund+ and VIB to establish ExeVir Bio for COVID-19 therapeutics development. UCB Ventures participated in the €42M Series A.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Leading European life sciences VC managing multiple billion-euro funds. Direct peer: invests in clinical-stage European therapeutics across all major indications, overlapping directly with Fund+'s therapeutic focus and stage range.

TypeDirect peer
Description

Dutch VC specialized in early-stage life sciences, frequently co-investing in Benelux biotechs. Direct peer: led TargED's recent Series A extension and competes for the same Belgian/Dutch biotech deal flow as Fund+.

TypeDirect peer
Description

French life sciences VC with €3.2B+ AUM. Direct peer: co-invests with Fund+ across multiple Belgian/Benelux portfolio companies (Tubulis, TargED) and targets the same European clinical-stage therapeutics market.

4EQT Life Sciences
TypeDirect peer
Description

Pan-European life sciences investor (formerly LSP), part of EQT. Direct peer: co-led Tubulis' €128M Series B2 and invests across European therapeutics at multiple stages, overlapping with Fund+'s focus on clinical-stage Belgian biotechs.

TypeDirect peer
Description

European life sciences-focused VC. Direct peer: participated in TargED Series A alongside Fund+ and invests across European clinical-stage therapeutics, making it a direct syndication peer.

TypeBroad incumbent
Description

Strategic life sciences investment arm of the Novo Nordisk Foundation. Broad incumbent: large-scale life sciences investor that, through acquisition of Cardior (Fund+ portfolio exit), has demonstrated both strategic acquirer and investor roles across the European biotech ecosystem.

TypeDirect peer
Description

Dutch VC with significant life sciences allocation. Direct peer: co-invested with Fund+ in TargED Biopharmaceuticals Series A and pursues similar early-to-mid-stage European biotech opportunities.

8Hadean Ventures
TypeDirect peer
Description

Nordic/European life sciences VC. Direct peer: co-led TargED Biopharmaceuticals' €39M Series A alongside Fund+ and focuses on Nordic and broader European clinical-stage biotechs in similar therapeutic areas.

TypeDirect peer
Description

Utrecht-based healthcare and life sciences VC. Direct peer: invests in European therapeutics and medical devices with similar geographic concentration to Fund+ in Benelux and surrounding markets.

TypeBroad incumbent
Description

Corporate venture arm of Boehringer Ingelheim. Broad incumbent: strategic life sciences investor providing capital plus partnership opportunities; while not a pure financial peer, it operates in the same European clinical-stage therapeutics deal flow as Fund+.

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment33 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fund+

Venture Capital / Life Sciences Investment Managementfundplus.be

Fund+ is a Belgian venture capital firm founded in 2015 that provides long-term equity investment to innovative life sciences companies across therapeutics, medical devices, and diagnostics, primarily in Belgium and the broader Benelux and European markets.

What Fund+ does

Fund+ is a Belgian venture capital firm established in 2015, headquartered at Groot Begijnhof 60 in Leuven. The firm operates as an open-ended fund providing long-term equity investment in innovative life sciences companies, with a primary focus on Belgium and the broader Benelux region while extending into select European markets including Germany, the Netherlands, and Spain. Fund+ invests across therapeutics, medical devices, and diagnostics, with a stated emphasis on patient-centric approaches addressing unmet medical needs in oncology, CNS disorders, rare diseases, infectious diseases, and regenerative medicine.

The firm manages a portfolio of approximately 16-17 companies spanning modalities such as antibody-drug conjugates (Tubulis, Ona Therapeutics), RNA therapeutics (Cardior), gene therapy (Coave Therapeutics), regenerative tissue products (Novadip Biosciences), vaccines (AstriVax Therapeutics), GPCR-modulating therapies (Confo Therapeutics), and continuous monitoring devices (Indigo Diabetes). Notable portfolio events include Fund+ leading the €42M Series A for ExeVir Bio (co-founded with VIB and UCB in 2020) and the €38M Series B for Indigo Diabetes, as well as participation in Tubulis' €60M Series B (2022), €128M Series B2 (2024), and €308M Series C (2025), the latter being the largest Series C financing for a European biotech.

Fund+'s revenue model combines management fees on assets under management with capital appreciation from equity investments realized through exits. As of 2022 the firm managed over €200M in AUM. Two major exits anchor the track record: Cardior's acquisition by Novo Nordisk in March 2024 for up to €1.025B, and Tubulis' acquisition by Gilead Sciences in April 2026 for $3.15B upfront plus up to $1.85B in milestone payments. The firm is led by founder and chairman Desire Collen and a specialist team combining healthcare industry, corporate finance, and strategy consulting experience, distributing capital via direct equity investments and active engagement with portfolio boards.

Fund+ firmographics

Firmographics
Name
Fund+
Legal name
Fundplus
Website
https://fundplus.be
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Fund+ is a Belgian venture capital firm founded in 2015 that provides long-term equity investment to innovative life sciences companies across therapeutics, medical devices, and diagnostics, primarily in Belgium and the broader Benelux and European markets.
Ownership category
akta.pro rank

Fund+ industry classification

Industry
Product category
Venture Capital / Life Sciences Investment Management
NAICS
Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds

Keywords

  • Life sciences venture capital
  • Biotech equity investment
  • Therapeutics funding
  • Medical devices investment
  • Diagnostics venture capital

Where Fund+ is headquartered

Location

Headquarters

HQ city
Leuven
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

Fund+ business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Capital Appreciation: Fund+ generates returns through capital appreciation from equity investments in portfolio companies. As an open-ended fund for long-term equity investment, returns are realized through exits of portfolio companies via acquisitions or IPOs.
  2. Investment Management Fees: Fund+ charges management fees for overseeing the fund and its portfolio companies, supporting companies throughout their growth cycle.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractLong-term equity investment in life sciences companies

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Fund+ product offering

Product offering

Core offering

Fund+ is an open-ended venture capital fund providing long-term equity investment to innovative European life sciences companies with a focus on Belgium and the Benelux region. The fund invests across stages in therapeutics, medical devices, and diagnostics companies addressing unmet medical needs, supporting them through their growth cycles with capital and strategic guidance.

Product overview

Fund+ is an open-ended venture capital fund for long-term equity investment in innovative European Life Sciences companies. The fund focuses on Belgium and Benelux, investing in therapeutics with a strong patient-centric approach and addresses unmet medical needs. Fund+ creates sustainable shareholder value while reinforcing Belgium's leading position in the Life Sciences sector and generating tangible societal benefits.

Differentiator

Problem solved

Functional benefit

Products and services

  • Fund+ Life Sciences Investment Fund An open-ended venture capital fund providing long-term equity investment to innovative European Life Sciences companies, with primary focus on Belgium and Benelux. Invests in therapeutics, medical devices, and diagnostics companies addressing unmet medical needs, with a patient-centric approach. Supports portfolio companies throughout their growth cycles from seed to later stages.

Quantifiable outcome

  • Tubulis acquisition by Gilead for $3.15B upfront + $1.85B milestones
  • +1 more outcomes

Companies that use Fund+

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles1 record

Fund+ technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Fund+ partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • ExeVir BiocoreStrategic or Co-development Partner · 1 January 2020Fund+ established ExeVir Bio with VIB and UCB in July 2020 to accelerate COVID-19 treatments. Fund+ led the €42M Series A. ExeVir develops single-domain antibody therapies for infectious diseases with candidates targeting SARS-CoV-2 variants and dengue.
  • VIBcoreStrategic or Co-development Partner · 1 January 2020VIB (Flanders Institute for Biotechnology) is Belgium's leading life sciences research institute. Fund+ co-founded ExeVir Bio with VIB and UCB. VIB provides scientific expertise and research capabilities for portfolio companies.
  • UCBminorStrategic or Co-development Partner · 1 January 2020UCB collaborated with Fund+ and VIB to establish ExeVir Bio for COVID-19 therapeutics development. UCB Ventures participated in the €42M Series A.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Fund+ competitors and assessment

Company assessment

Direct peers

  • Forbion: Leading European life sciences VC managing multiple billion-euro funds. Direct peer: invests in clinical-stage European therapeutics across all major indications, overlapping directly with Fund+'s therapeutic focus and stage range.
  • BioGeneration Ventures: Dutch VC specialized in early-stage life sciences, frequently co-investing in Benelux biotechs. Direct peer: led TargED's recent Series A extension and competes for the same Belgian/Dutch biotech deal flow as Fund+.
  • Andera Partners: French life sciences VC with €3.2B+ AUM. Direct peer: co-invests with Fund+ across multiple Belgian/Benelux portfolio companies (Tubulis, TargED) and targets the same European clinical-stage therapeutics market.
  • EQT Life Sciences: Pan-European life sciences investor (formerly LSP), part of EQT. Direct peer: co-led Tubulis' €128M Series B2 and invests across European therapeutics at multiple stages, overlapping with Fund+'s focus on clinical-stage Belgian biotechs.
  • Sunstone Life Science Ventures: European life sciences-focused VC. Direct peer: participated in TargED Series A alongside Fund+ and invests across European clinical-stage therapeutics, making it a direct syndication peer.
  • Inkef Capital: Dutch VC with significant life sciences allocation. Direct peer: co-invested with Fund+ in TargED Biopharmaceuticals Series A and pursues similar early-to-mid-stage European biotech opportunities.
  • Hadean Ventures: Nordic/European life sciences VC. Direct peer: co-led TargED Biopharmaceuticals' €39M Series A alongside Fund+ and focuses on Nordic and broader European clinical-stage biotechs in similar therapeutic areas.
  • Gilde Healthcare: Utrecht-based healthcare and life sciences VC. Direct peer: invests in European therapeutics and medical devices with similar geographic concentration to Fund+ in Benelux and surrounding markets.

Broad incumbents

  • Novo Holdings (Novo Seeds / Novo Ventures): Strategic life sciences investment arm of the Novo Nordisk Foundation. Broad incumbent: large-scale life sciences investor that, through acquisition of Cardior (Fund+ portfolio exit), has demonstrated both strategic acquirer and investor roles across the European biotech ecosystem.
  • Boehringer Ingelheim Venture Fund: Corporate venture arm of Boehringer Ingelheim. Broad incumbent: strategic life sciences investor providing capital plus partnership opportunities; while not a pure financial peer, it operates in the same European clinical-stage therapeutics deal flow as Fund+.

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Fund+ financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fund+ leadership team

Management profile

Number of profiles

Profiles1 record

Fund+ funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fund+ M&A and investment

M&A and investment

M&A

Investments33 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fund+

What does Fund+ do?

Fund+ is an open-ended venture capital fund providing long-term equity investment to innovative European life sciences companies with a focus on Belgium and the Benelux region. The fund invests across stages in therapeutics, medical devices, and diagnostics companies addressing unmet medical needs, supporting them through their growth cycles with capital and strategic guidance.

Is Fund+ a public or private company?

Fund+ is a private company. It is classified as venture growth investor backed and is currently operating.

When was Fund+ founded?

Fund+ was founded in 2015. It employs 1 to 10 people.

Where is Fund+ based?

Fund+ is headquartered in Leuven, Belgium, in the Europe region.

How does Fund+ make money?

Two revenue lines are on record. Capital Appreciation is the primary driver. The others are investment Management Fees.

Who are Fund+'s main competitors?

Direct peers on record are Forbion, BioGeneration Ventures, Andera Partners, EQT Life Sciences, Sunstone Life Science Ventures, Inkef Capital, Hadean Ventures and Gilde Healthcare. Broad incumbents are Novo Holdings (Novo Seeds / Novo Ventures) and Boehringer Ingelheim Venture Fund.

Does Fund+ have an API?

No public API is recorded for Fund+.

What industry is Fund+ in?

Fund+'s product category is Venture Capital / Life Sciences Investment Management. Its primary akta.pro industry code is FSANAJAN, SDG / Thematic Sustainable Investment Funds. Its NAICS code is 5259 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals